Objective:

To evaluate the safety and dose determination of 4D-150 for diabetic macular edema (DME) in the SPECTRA trial.

Approach:

Key Findings:

• The drug 4D-150 demonstrated excellent safety with no intraocular inflammation (IOI) events.
• A significant dose response was observed, with a 9.7 letter increase in visual acuity at the high dose.
• There was a corresponding decrease in central subfield thickness, indicating effective treatment.

Interpretation:

The dual transgene approach of 4D-150, combining aflibercept and an RNAi molecule targeting VEGF-C, appears to be effective without inciting inflammatory reactions.

Conclusion:

The intravitreal mode of delivery for 4D-150 is promising for large-scale application in treating DME.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.